# Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

> **NCT03360929** · PHASE1,PHASE2 · COMPLETED · sponsor: **LYZZ Alpha Holding Ltd** · enrollment: 15 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AZD3759

## Key facts

- **NCT ID:** NCT03360929
- **Lead sponsor:** LYZZ Alpha Holding Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-30
- **Primary completion:** 2020-11-13
- **Final completion:** 2020-11-13
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03360929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03360929, "Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03360929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*